Perceptive Advisors LLC Buys 2,938,500 Shares of Dyne Therapeutics, Inc. $DYN

Perceptive Advisors LLC increased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 543.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,478,944 shares of the company’s stock after acquiring an additional 2,938,500 shares during the period. Dyne Therapeutics accounts for 1.2% of Perceptive Advisors LLC’s holdings, making the stock its 25th largest position. Perceptive Advisors LLC’s holdings in Dyne Therapeutics were worth $68,048,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Strs Ohio bought a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $51,000. Aster Capital Management DIFC Ltd bought a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $84,000. Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Dyne Therapeutics by 275.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. Finally, Prudential Financial Inc. bought a new position in shares of Dyne Therapeutics during the 2nd quarter worth approximately $111,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Up 6.3%

Shares of DYN opened at $19.20 on Thursday. The stock has a fifty day moving average price of $18.27 and a two-hundred day moving average price of $18.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The company has a market cap of $3.17 billion, a price-to-earnings ratio of -5.96 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) earnings per share. Analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director owned 11,663 shares in the company, valued at approximately $229,527.84. The trade was a 96.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 1,559,462 shares valued at $29,814,746. Insiders own 9.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Morgan Stanley cut their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.85.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.